Rademikibart Improves Lung Function in Patients with Asthma within 24 Hours
This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.
Related Articles
Sage Therapeutics gets acquired by Maryland drugmaker for up to $795 million
Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to $795 million.
Spreading Joy for Jordan: A Citywide Celebration of Childhood Wellness and Literacy | Urban Health Institute
What if one day of joy could brighten a lifetime of pain? On Wednesday, June 18, Baltimore will come together for the inaugural Joy for…
Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients
Melodie Young, MSN, AGNP-C, FSDNP, DCNP; TJ Chao, MPAS, PA-C; Leigh Ann Pansch, MSN, FNP-BC, DCNP; and Douglas DiRuggiero, DMSc, MHS, PA-C, discuss how the…
Lilly’s amylin candidate shows early promise
Plus more biotech news stories, brought to you by The Readout.
Allergy | Medical News & Expert Perspectives | HCPLive
The allergy condition center is a comprehensive resource for clinical news and expert insights on allergy. Read more at HCPLive.
Pharmalittle: We’re reading about a Sarepta setback with a DMD drug, FDA workload causes a delay, and more
In today’s Pharmalittle roundup, we’re reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a delay, and more.
Predicting Cardiovascular Disease in Patients Without Risk Factors with Matthew Budoff, MD
Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.
Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD
In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.
FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
Parent company Amneal Pharmaceuticals, Inc. has announced intentions to launch the topical anti-inflammatory agent in the third quarter of 2025.
Leveraging SGLT2 Inhibitors, GLP-1 RAs in Heart Failure, with Jose Lopez, MD
Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.